VANCOUVER, British Columbia–(BUSINESS WIRE)–September 26, 2022–

Wellbeing Digital Science Co., Ltd. (” wellbeing” or ” Company ”) (NEO: Medi ) (over the counter: Konev ) (FRA: SQ2 ), a wholly owned subsidiary of KGK Sciences Inc. (“ KGK”) has announced that it has opened. The new clinical research center in London, Ontario aims to accelerate clients’ research and drug development needs in the areas of nutraceuticals, cannabinoids, hemp and psychedelics.

KGK will hold a grand opening ceremony on September 29, 2022 to officially inaugurate its new state-of-the-art clinical research facility and celebrate over 25 years of being a leading contract research institution. The company’s clinical research center powers his KGK to provide high-quality clinical research trials and expert regulatory support to clients in the nutraceutical, cannabis, hemp and psychedelic industries.

KGK is a premium full-service contract research organization dedicated to providing clinical trial research that meets the highest quality standards. Led by a team of scientific research and regulatory experts, KGK combines cutting-edge clinical science and industry expertise to design clinical trials and proof-of-claim strategies customized to meet client needs. With more than 150 publications, the company continues to push the industry for study design and measurement tools, most recently published in Frontiers Journal on evaluating and re-evaluating clinical trial design. Read the full article here: Breaking new frontiers: Assessment and re-evaluation of Clinical Trial design for nutraceuticals.

“Our new research center in the heart of London, Ontario will leverage our strength and heritage in applied research and innovation to continue our groundbreaking research in the fields of nutraceuticals, cannabinoids, hemp and hallucinogens. Najla Guthrie, CEO of Wellbeing & KGK, said: “Our goal is to strengthen the basic research needed for global innovation and develop the next generation of nutritional supplements. and enable the creation of pharmaceuticals.”

Media interested in attending the opening should contact Natalie Dolphin at ndolphin@wellbeingdigital.co, phone: 416-706-6364 by 12:00 PM ET on Thursday, September 29, 2022. is needed.

About KGK Science

KGK, a subsidiary of Wellbeing Digital Sciences, is a leading North American contract research organization based in London, Ontario, providing high-quality clinical research trials focused primarily on nutritional supplements and emerging healthcare products. doing. Founded in 1997, the business has successfully assisted hundreds of companies in conducting custom-designed clinical trials and demonstrating strategies to bring their products to global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Additionally, the company has produced over 150 of his publications, conducted over 400 clinical trials in over 40 indications, and in its database he has amassed 25,000 participants and collected 10 million data points. did. For more information, please visit kgkscience.com.

About Wellbeing Digital Science

Wellbeing Digital Sciences Inc. is an evidence-based mental health company focused on developing and implementing innovative clinical therapeutic solutions, including psychedelic medicine and digital therapeutics, supported by clinical research. Its mission is supported by a network of North American clinics that provide advanced therapeutics and other types of treatment to patients, and a contract research organization that provides clinical trial services to clients pursuing drug development. For more information, visit wellbeingdigital.co.

on behalf of:

Naira Guthrie

Chief executive officer

Wellbeing Digital Science

Forward-Looking Notice:

This news release contains forward-looking statements, including, but not limited to, statements regarding our business, assets or investments and other statements that are not statements of historical fact. Readers are cautioned not to place undue reliance on forward-looking statements. There is no guarantee that the plans, intentions or expectations on which it is based will come to fruition. By their very nature, forward-looking statements involve a number of assumptions involving both general and specific known and unknown risks and uncertainties and are subject to projections, projections, forecasts and other forward-looking statements. Contributes to the possibility that the description about will not occur. future performance or results that differ materially from our estimates or projections of future performance or results expressed or implied by such forward-looking statements; These assumptions, risks and uncertainties include, among other things, general economic conditions, particularly the capital markets, investor interest in our business and our outlook.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, we may update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. disclaims intent and assumes no liability. Further, we do not undertake any obligation to comment on any third party expectations or statements with respect to the above matters.

View source version at businesswire.com: https://www.businesswire.com/news/home/20220926005255/en/

Contact: For more information, please contact:

Natalie Dolphin

Vice President of Marketing and Investment Relations

Email: ndolphin@wellbeingdigital.co

Twitter: @Wellbeing_IR

Keywords: United States North America Canada

Industry Keywords: Biotechnology Alternative Medicine Health Cannabis Medicine Hemp Mental Health Natural Resources Research Science Clinical Trials

Source: Wellbeing Digital Sciences Inc.

Copyright Business Wire 2022.

PUB: 2022/09/26 07:30 AM/DISC: 2022/09/26 07:32 AM

http://www.businesswire.com/news/home/20220926005255/en